טוען...
Bortezomib for the treatment of mantle cell lymphoma: an update
Bortezomib is a first in class proteasome inhibitor, initially approved by the US Food and Drug Administration for the treatment of plasma cell myeloma. Bortezomib has been approved for the treatment of relapsed and refractory mantle cell lymphoma (MCL) and, more recently, in the upfront setting as...
שמור ב:
| הוצא לאור ב: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959639/ https://ncbi.nlm.nih.gov/pubmed/27493710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716648566 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|